Leyden Labs secures €40 million to develop intranasal protectio…

According to EU-Startups, homeFundingLeyden Labs secures €40 million to develop intranasal protection against influenza and… HomeFundingLeyden Labs secures €40 million to develop intranasal protection against influenza and…FundingNetherland-Startups Leyden Labs secures €40 million to develop intranasal protection against influenza and coronaviruses By David Cendon Garcia June 25, 2026 Share FacebookTwitterWhatsAppLinkedin Following their selection for the EIC STEP Scale Up programme, Dutch BioTech startup Leyden Labs has raised €40 million to advance its nasal spray platform designed to protect against influenza and other respiratory viruses.The round brings together the European Innovation Council (EIC) Fund, Invest-NL, the Gates Foundation Strategic Investment Fund, ClavystBio, and others, with Invest-NL contributing €10 million.Key players involved: Goldman Sachs Asset Management, GI Partners This development has significant implications for the industry, potentially influencing competitive dynamics, investment patterns, and strategic priorities across the sector. “It signals confidence in our scientific approach, our team, and our mission to fundamentally improve how the world protects itself against respiratory viruses. Market ImplicationsForward-Looking IndicatorsContinued consolidation expected in the sectorIncreasing focus on digital transformation and innovationGrowing importance of ESG considerations Expert Commentary Looking AheadFor complete details on this development, refer to the original report from EU-Startups. Frequently Asked Questions